Want to stay in touch with the latest updates from Pharmaceutical Business review? That's easy! Just subscribe clicking the Follow button below, choose topics or keywords for filtering if you want to, and we send the news to your inbox, to your phone via push notifications or we put them on your personal page here on follow.it.
Reading your RSS feed has never been easier!
Website title: Pharmaceutical Business review
Is this your feed? Claim it!
The collaboration aims to conduct a full technical and operational assessment of Cellares’ automated manufacturing and testing platforms.
This is in preparation for the anticipated demand surrounding TSC-101 as it advances towards a pivotal clinical trial scheduled to start in the second quarter (Q2) of 2026.
Under the agreement, Cellares will use its Cell Shutt...
The collaboration combines CytomX’s Probody technology with Regeneron’s Veloci‑Bi bispecific platform to target hard‑to‑treat tumour types.
Established in 2022, the partnership combines CytomX’s biologic masking technology with Regeneron’s expertise in bispecific antibodies.
The therapies are designed to stay inactive until proteases in the tumour microenvironme...
This marks the second indication for Aquipta in the EU, where it is now approved both for acute attacks and as a once-daily preventive treatment for adults experiencing four or more migraine days each month.
Migraine is a common and disabling neurological condition characterised by intense headaches, cognitive impairment, sensitivity to light and sound, and nausea, all...
The application seeks approval of giredestrant as an adjuvant treatment for adults with oestrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, stage I to III breast cancer.
A decision from the FDA is anticipated by 30 November 2026.
Roche chief medical officer and global product development head Levi Garraway said: “Giredestr...
The regulator granted the application priority review for this indication, assigning a Prescription Drug User Fee Act (PDUFA) date of 30 September 2026.
Camzyos is currently approved for symptomatic New York Heart Association (NYHA) Class II-III oHCM in adults to improve functional capacity and symptoms and has so far been prescribed by more than 4,500 healthcare provi...